Samphire Neuroscience
Developer of brain‑first, non‑pharmacologic wearable tools and a companion mobile application for menstrual health. The organisation designs home‑use, low‑intensity neurostimulation devices paired with a mobile app for cycle tracking, personalized protocols and integration with third‑party wearables. Activities include randomized, placebo‑controlled clinical trials, published research, academic and clinical partnerships, regulatory conformity in Europe/UK, and deployment through consumer and employer channels with subscription-based digital care.
Industries
Nr. of Employees
small (1-50)
Products
Medical wearable for menstrual pain and mood relief
A medically certified, consumer wearable that delivers gentle non‑invasive brain stimulation intended to reduce menstrual pain and cycle‑linked mood symptoms when used at home and paired with a companion mobile application.
Wearable device for hormonal wellbeing (North American market)
A consumer wearable device based on the same neurostimulation approach, positioned for availability outside the European Union and paired with the companion application for cycle‑linked wellbeing support.
Cycle‑tracking and personalization mobile application
Mobile application for logging symptoms (structured and free text), visualizing patterns by cycle phase, delivering tailored behavioral recommendations and pairing with wearable devices for enhanced predictions.
Medical wearable for menstrual pain and mood relief
A medically certified, consumer wearable that delivers gentle non‑invasive brain stimulation intended to reduce menstrual pain and cycle‑linked mood symptoms when used at home and paired with a companion mobile application.
Wearable device for hormonal wellbeing (North American market)
A consumer wearable device based on the same neurostimulation approach, positioned for availability outside the European Union and paired with the companion application for cycle‑linked wellbeing support.
Cycle‑tracking and personalization mobile application
Mobile application for logging symptoms (structured and free text), visualizing patterns by cycle phase, delivering tailored behavioral recommendations and pairing with wearable devices for enhanced predictions.
Services
Provisioning of wearable devices and digital memberships as an employee benefit, including onboarding, integration with wellbeing platforms, and dedicated support for employers and participants.
Consumer subscription service providing personalized app content, guided practices (meditation, breathwork), cycle predictions and integration with devices for symptom management.
Tailored support for researchers and clinical teams including trial partnership, access to device technology for pilots, and a clinical contact team for study coordination.
Provisioning of wearable devices and digital memberships as an employee benefit, including onboarding, integration with wellbeing platforms, and dedicated support for employers and participants.
Consumer subscription service providing personalized app content, guided practices (meditation, breathwork), cycle predictions and integration with devices for symptom management.
Tailored support for researchers and clinical teams including trial partnership, access to device technology for pilots, and a clinical contact team for study coordination.
Expertise Areas
- Non‑invasive neurostimulation for symptom modulation
- Clinical trial management and randomized controlled trials
- Digital health and mobile symptom‑tracking platforms
- Women’s health and menstrual disorder interventions
Key Technologies
- Transcranial direct current stimulation (tDCS‑style protocols)
- Wearable neurostimulation hardware
- IoT connectivity and device‑to‑app synchronization
- Mobile health (mHealth) applications
News & Updates
Announcement describing a new wearable release for the US market and how it relates to product technology available in other regions.
Article explaining links between menstrual pain and brain mechanisms and how neurostimulation approaches may provide relief.
Summary of user‑reported outcomes from a six‑month survey reporting reduced sick days and lower medication reliance.
Company‑reported randomized, double‑blind trial (WIND 2024) indicating a high proportion of users reported symptomatic improvement within three months.
Product listed with medical device regulatory classification for use in the European Union and United Kingdom.
Reported usability and survey metrics from internal studies and user surveys (examples reported on the site: ease of integration, early symptom improvement and medication reduction metrics).
Announcement describing a new wearable release for the US market and how it relates to product technology available in other regions.
Article explaining links between menstrual pain and brain mechanisms and how neurostimulation approaches may provide relief.
Summary of user‑reported outcomes from a six‑month survey reporting reduced sick days and lower medication reliance.
Company‑reported randomized, double‑blind trial (WIND 2024) indicating a high proportion of users reported symptomatic improvement within three months.
Product listed with medical device regulatory classification for use in the European Union and United Kingdom.
Reported usability and survey metrics from internal studies and user surveys (examples reported on the site: ease of integration, early symptom improvement and medication reduction metrics).